- Home
- TCRX vs TVGN Comparison
TCRX vs TVGN Comparison
Compare TCRX & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCRX | TVGN |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.1M | 63.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TCRX | TVGN |
|---|---|---|
| Price | $0.98 | $6.29 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 509.6K | 22.3K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,325,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 266.65 | N/A |
| 52 Week Low | $0.83 | $0.14 |
| 52 Week High | $2.57 | $12.03 |
Technical Indicators
Market Signals| Indicator | TCRX | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.76 | 36.01 |
| Support Level | $0.90 | $6.33 |
| Resistance Level | $1.16 | $11.60 |
| Average True Range (ATR) | 0.09 | 1.33 |
| MACD | 0.01 | -0.45 |
| Stochastic Oscillator | 61.86 | 1.39 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.